Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:63
  • preuzimanja u poslednjih 30 dana:5

Sadržaj

članak: 3 od 89  
Back povratak na rezultate
2021, vol. 71, br. 4, str. 354-364
Modelovanje u farmakoekonomskim evaluacijama lekova
Univerzitet u Beogradu, Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo

e-adresadragana.lakic@pharmacy.bg.ac.rs
Ključne reči: farmakoekonomske evaluacije; modelovanje; drvo odlučivanja; Markovljev model
Sažetak
Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.
Reference
*** (2015-2019) Uredba o kriterijumima za formiranje cena lekova za upotrebu u humanoj medicine čiji je režim izdavanja na recept. Službeni glasnik RS, 86/15, 8/16, 15/18, 18/19
*** (2014-2018) Pravilnik o uslovima, kriterijumima, načinu i postupku za stavljanje leka na listu lekova, izmene i dopune liste lekova, odnosno za skidanje leka sa Liste lekova. Službeni glasnik RS, 41/14, 125/14, 48/15, 14/18
Ademi, Z., Kim, H., Reid, C.M., Hollingsworth, B., Liew, D. (2012) Overview of Pharmacoeconomic Modelling Methods. Br J Clin Pharmacol, 75(4): 944-50
Barton, P., Bryan, S., Robinson, S. (2004) Modelling in the Economic Evaluation of Health Care: Selecting the Appropriate Approach. J Health Serv Res Policy, 9(2): 110-118
Basu, S. (2018) Modelling Public Health and Healthcare Systems. New York: Oxford University Press, 125-145
Bogavac-Stanojevic, N., Dopsaj, V., Jelic-Ivanovic, Z., Lakić, D., Vasić, D., Petrova, G. (2013) Economic Evaluation of Different Screening Alternatives for Patients with Clinically Suspected Acute Deep Vein Thrombosis. Biochemia Medica, 23(1): 96-106
Bootman, J.L., Townsend, R.J., Mcghan, W.F. (2005) Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books, 1-18, 3rd Ed
Boyd, K.A., Fenwick, E., Briggs, A. (2010) Using an Iterative Approach to Economic Evaluation in the Drug Development Process. Drug Develop Res, 71(8): 470-477
Brennan, A., Chick, S.E., Davies, R. (2006) A Taxonomy of Model Structures for Economic Evaluation of Health Technologies. Health Econ, 15(12): 1295-310
Briggs, A., Claxton, C., Sculpher, M. (2006) Decision Modelling for Health Economic Evaluation. New York: Oxford University Press, 27-44
Cleemput, I., van Wilder, P., Huybrechts, M., Vrijens, F. (2009) Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Requests. Value Health, 12: 441-449
Cookson, R., Griffin, S., Norheim, O.F., Culyer, A. (2021) Distributional Cost-Effectiveness Analysis. New York: Oxford University Press, 137-138
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G. (2005) Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press, 65-69. 3rd Ed
Dutina, A., Stašević-Karličić, I., Pandrc, N., Prokić, A., Janković, S.M. (2019) Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia. Srpski arhiv za celokupno lekarstvo, vol. 147, br. 7-8, str. 468-474
Gray, A., Clarke, P., Wolstenholme, J., Wordsworth, S. (2010) Applied Methods of Cost-effectiveness Analysis in Health Care. New York: Oxford University Press, 179-210
Kostić, M., Milosavljević, M.N., Stefanović, S., Ranković, G., Janković, S.M. (2020) Cost-utility of Tafenoquine Vs. Primaquine for the Radical Cure (prevention of Relapse) of Plasmodium Vivaxmalaria. J Chemother, 32(1): 21-29
Kostić, M., Jovanović, S., Tomović, M., Popović-Milenković, M., Janković, S.M. (2014) Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: A Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanitetski pregled, vol. 71, br. 2, str. 144-148
Lakic, D., Petrova, G., Bogavac-Stanojevic, N., Jelic-Ivanovic, Z., Kos, M. (2012) The Cost-effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model. Biotechnol & Biotechnol Eq, 26(3): 3066-72
Lakic, D., Bogavac-Stanojevic, N., Jelic-Ivanovic, Z., Kotur-Stevuljevic, J., Spasic, S., Kos, M. (2010) A Multimarker Approach for the Prediction of Coronary Artery Disease: Cost-Effectiveness Analysis. Value Health, 13(6): 770-777
Lakić, D., Tadić, I., Odalović, M., Kolundžić, S. (2015) Upotreba antibakterijskih lekova u lečenju infekcija urinarnog trakta - farmakoekonomski aspect. Arhiv za farmaciju, vol. 65, br. 1, str. 47-57
Lakić, D., Petrović, B., Petrova, G. (2014) Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data. Srpski arhiv za celokupno lekarstvo, vol. 142, br. 11-12, str. 688-694
Petrou, S., Gray, A. (2011) Economic Evaluation Alongside Randomised Clinical Trials: Design, Conduct, Analysis, and Reporting. BMJ, 342: d1548
Petrou, S., Gray, A. (2011) Economic Evaluation Using Decision Analytical Modelling: Design, Conduct, Analysis, and Reporting. BMJ, 342: d1766
Petrovic, S., Bogavac-Stanojevic, N., Lakic, D., Peco-Antic, A.E., Vulicevic, I., Ivanisevic, I., et al. (2015) Costeffectiveness Analysis of Acute Kidney Injury Biomarkers in Pediatric Cardiac Surgery. Biochemia Medica, 25(2): 262-271
Piniazhko, O., Zaliska, O., Nemeth, B. (2017) Development of Pharmacoeconomic Guidelines In Ukraine: Methodological Issues And Policy Implications. Value Health, 20(9): A669-A700
Rascati, K.L. (2013) Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins, 2nd Ed., 3-6
Squires, H., Boyd, K. (2019) The Use of Modelling Approaches for the Economic Evaluation of Public Health Intervention. u: Rhiannon T. Edwards; Mcintosh E [ur.] Applied health economics for public health practise and research, New York: Oxford University Press, 248-273
Squirres, H., Chilcott, J., Akehurst, R., Burr, J., Kelly, M.P. (2016) A Framework for Developing the Structure of Public Health Economic Models. Value Health, 19(5): 588-601
Stojković, T., Marinković, V., Lakić, D., Bogavac-Stanojević, N. (2016) Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin. Arhiv za farmaciju, vol. 66, br. 2, str. 103-117
Whitehead, S.J., Ali, S. (2010) Health Outcomes in Economic Evaluation: the QALY and Utilities. Br Med Bull, 96(1): 5-21
Živković, M., Lakić, D., Tadić, I., Odalović, M., Bogavac-Stanojević, N. (2015) Farmakoekonomska evaluacija primene rastvora za infuziju kaspofungina i amfotericina B u terapiji teških sistemskih mikoza. Arhiv za farmaciju, vol. 65, br. 1, str. 33-46
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/arhfarm71-32404
objavljen u SCIndeksu: 03.09.2021.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0

Povezani članci